Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 9.81% of ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the ...

Foghorn Therapeutics Inc. (FHTX) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than in ...

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's ...

We recently compiled a list of the 7 Unstoppable Growth Stocks To Buy Now. In this article, we are going to take a look at ...

VO659 is generally safe and well tolerated with an anticipated dosing regimen of 1-2 times per year in future studies LEIDEN, Netherlands, Sept. 13, 2024 /PRNewswire/ -- Vico Therapeutics B.V., a ...

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

Oppenheimer has recently resumed Gain Therapeutics Inc (GANX) stock to Outperform rating, as announced on August 14, 2024, according to Finviz. Earlier, on April 12, 2021, Oppenheimer had initiated ...

Relay originally announced Monday it was seeking to raise gross proceeds of $200 million in a fresh offering of its common stock. After market hours the following day it provided more detail, stating ...